Key facts
- Notable investors include Creative Destruction Lab, Biolife Solutions, BroadOak Capital Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pluristyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Pluristyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pluristyx
Developer of cell and gene therapy designed to solve manufacturing challenges faced during drug development and regenerative medicine. The company offers pluripotent stem cell manufacturing, contract development, and manufacturing services, along with providing expertise and tools to support and accelerate the development and commercialization of therapeutics to treat serious human diseases, enabling the healthcare industry to improve the treatment process and efficiency.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2018
- Employees
- 15
- Website
- pluristyx.com/
- Ownership
- Privately Held (backing)
Pluristyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pluristyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pluristyx in its N-PORT filings yet. We sweep new filings monthly.